QUOTE AND NEWS
Motley Fool  Dec 12  Comment 
Is this meaningful? Or just another movement?
Benzinga  Dec 12  Comment 
ChemoCentryx Inc (NASDAQ: CCXI) gained more than 70 percent Friday on news that its lead drug candidate met with success in a Phase II study. Shares of the company changed hands recently at $7.57, up 68 percent. Chief Executive Thomas J....
FierceBiotech  Dec 12  Comment 
A year after former partner GlaxoSmithKline closed the door on what could have been a $1.5 billion collaboration, Mountain View, CA's ChemoCentryx is touting a Phase II victory for its kidney disease treatment, news that promptly doubled its share...
Benzinga  Dec 12  Comment 
ChemoCentryx (NASDAQ: CCXI) shares surged 104.90% to $9.20 in pre-market trading as primary endpoint achieved in Phase II CCX140 trial. Adobe Systems (NASDAQ: ADBE) shares jumped 7.47% to $74.95 in pre-market trading after the company posted...
Benzinga  Dec 4  Comment 
ChemoCentryx, Inc., (Nasdaq: CCXI), a clinical-stage biopharmaceutical company focused on autoimmune diseases, inflammatory disorders and cancer, reported today that the European Commission has granted orphan medicinal product designation for...
newratings.com  Nov 6  Comment 
WASHINGTON (dpa-AFX) - ADMA Biologics Inc.'s (ADMA.OB) common stock has been approved for listing on the NASDAQ Capital Market beginning on November 10, 2014 under the symbol "ADMA". The company expects to provide top-line, preliminary...
newratings.com  Oct 22  Comment 
CAMBRIDGE (MASSACHUSETTS) (dpa-AFX) - ChemoCentryx Inc.'s (CCXI) phase I trial of CCX507 has demonstrated that the compound is safe and well tolerated in healthy volunteers at all doses tested. CCX507 is being evaluated for treatment of...
Benzinga  Oct 20  Comment 
ChemoCentryx, Inc., (Nasdaq: CCXI), a clinical-stage biopharmaceutical company focused on autoimmune diseases, inflammatory disorders and cancer, today reported data from the Phase III SHIELD 4 clinical trial in Crohn's disease with vercirnon, an...




 

ChemoCentryx, Inc. (NASDAQ:CCXI) is a biotechnology company which is developing drugs to help treat Crohn's disease and rheumatoid arthritis. The company's focus has been to target the chemokine system, a system which is known to drive the inflammation process. Using its research platform, Chemocentryx plans to develop future drugs built around targeting the same or similar systems. At the time of its IPO, Chemocentryx did not have any FDA approved drugs.[1]


Business Overview

Chemocentryx was pre-commercially approved drug at the time of its IPO. As a result, its revenues were from collaborative research. In the first nine months of 2011, they reported $5.6M of such revenues and a net loss of $22.8M. The same period in the previous year resulted in $21.7M in revenues and a net loss of $8.2M. [2]

New Updates

The company's initial public offering of stock on the NASDAQ occurred on February 8, 2012. The company offered 4.5M shares each for $10. This was below the $14-$16 initial price range. The deal raised a total of $45M. The lead mangers of the deal were JP Morgan, Citi, and Cowen Group (COWN).[3]

Trends & Forces

Reliance on Large Pharmaceutical Companies

Chemocentryx has entered into strategic agreements with GlaxoSmithKline (GSK). These agreements provide for Chemocentryx to conduct the initial clinical trials of candidate drugs and for GSK to pay for and complete the Phase III as well as the marketing and commercialization. Through this agreement, GSK is given the option to exlusively license Chemocentryx's product. While this agreement passes risks and costs associated with drug development to GSK, it also makes Chemocentryx reliant on GSK's abilities to conduct advanced clinical trials and effectively commercialize a product. [4]

  1. CCXI S-1/A 2012 PROSPECTUS SUMMARY "Overview" pg1-3
  2. CCXI S-1/A 2012 PROSPECTUS SUMMARY "SUMMARY FINANCIAL DATA" pg. 9
  3. Renaissance Capital - IPO Home "ChemoCentryx prices downsized IPO at $10, below the range" 8 Feb 2012
  4. CCXI S-1/A 2012 PROSPECTUS SUMMARY "Risk Factors" pg11-13
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki